Clinical Trial

Estradiol-mediated Inflammation and Central Sensitization in the Pathophysiology of Endometriosis-associated Pelvic Pain

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to better understand how hormone suppression with Relugolix Combination-Therapy (CT) affects pelvic pain, inflammation, and pain sensitivity in women with moderate-to-severe endometriosis associated pelvic pain.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-07-27; most recent amendment 2026-02-13.
Status change: Not Yet Recruiting → Recruiting 2025-08-12
Trial Details
NCT Number NCT07100782
Lead Sponsor University of Michigan
Collaborators: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Conditions Endometriosis, Pelvic Pain
Enrollment 130 participants
Start Date 2025-12-08
Primary Completion 2028-08 (estimated)
Study Completion 2028-09 (estimated)
Updated on ClinicalTrials.gov 2026-02-18